Sarah K Tasian, MD
Hematologic Malignancies section
3501 Civic Center Boulevard, CTRB 3010
Philadelphia, PA 19104
BS, BA (Biological Sciences, Psychology)
University of Notre Dame, 1999.
Baylor College of Medicine, 2004.
Description of Clinical ExpertiseI have clinical expertise in the care of children, adolescents, and young adults with hematologic malignancies, particularly those with acute lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), chronic myeloid leukemia (CML), and juvenile myelomonocytic leukemia (JMML). My particular clinical interests include integration of comprehensive leukemia genetic data with therapy selection for children with high risk newly-diagnosed and relapsed ALL and AML with a focus on precision medicine treatment approaches.
I attend on the Hematologic Malignancies inpatient service and outpatient Oncology clinic at the Children's Hospital of Philadelphia. I have procedural expertise in bone marrow aspiration and biopsy, lumbar punctures (spinal taps), Ommaya reservoir taps, administration of intrathecal chemotherapy, and skin biopsies.
Description of Other ExpertiseI am a primary clinical mentor in Hematologic Malignancies for first, second, and third year pediatric hematology-oncology fellows and supervise their patient care in the inpatient and outpatient clinical settings. I also teach and supervise pediatric residents in the inpatient setting.
Description of Research ExpertiseMy career goal as an academic physician-scientist is to develop molecularly-targeted therapies for children with high-risk leukemias to prevent relapse, improve survival, and minimize toxicities.
My independent translational research program focuses upon novel therapeutics for high-risk pediatric leukemias via:
(1) Characterization of signal transduction networks and preclinical testing of kinase inhibitors for subtypes of acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML)
(2) Preclinical testing of leukemia antigen-redirected chimeric antigen receptor (CAR) T cell immunotherapy for childhood AML and ALL
(3) Early phase clinical trial testing of targeted therapies for children with leukemia through the Children’s Oncology Group (COG) and other consortia
Successful integration of our bench-based and clinical studies has led to several trials testing new therapies in children with high-risk leukemias. I have leadership roles in the COG ALL, Myeloid Diseases, and AML New Agents steering committees and am the COG Developmental Therapeutics Committee Vice Chair of Biology for Hematologic Malignancies. I also chair the COG phase 2 clinical trial AALL1521 (ruxolitinib/chemotherapy for children with CRLF2/JAK pathway-mutant Ph-like ALL), co-lead development of immunotherapy trials for children with relapsed AML, and am PI of the CHOP Center for Childhood for Cancer Research leukemia biorepository.
Current Tasian laboratory members and collaborators:
Asen Bagashev, PhD (research associate/scientist)
John Chukinas, BS (research technician)
Yang Ding, MD (post-doctoral fellow/instructor)
David Hottman Allen, PhD (post-doctoral fellow)
Christian Hurtz, PhD (research associate/scientist)
JP Loftus, BS (research technician)
Lisa Niswander, MD PhD (post-doctoral fellow)
Sisi Zheng, MD (post-doctoral fellow)
Selected PublicationsBonifant Challice L, Tasian Sarah K: The future of cellular immunotherapy for childhood leukemia. Current opinion in pediatrics 32(1): 13-25, Feb 2020.
Harvey RC and Tasian SK: Clinical diagnostics and treatment strategies for Philadelphia chromosome-like acute lymphoblastic leukemia. Blood Advances 4(1): 218-228, Jan 2020.
Lamble AJ, Eidenschink Brodersen L, Alonzo TA, Wing J, Gerbing RB, Pardo L, Sung L, Tasian SK, Cooper TM, Kolb EA, Aplenc R, Loken MR, Meshinchi S: Correlation of CD123 Expression Level with Disease Characteristics and Outcomes in Pediatric Acute Myeloid Leukemia: A Report from the Children’s Oncology Group. Blood Page: abstract #459, December 2019 Notes: Oral presentation at ASH annual meeting given by collaborator; Orlando, Florida.
Pufall MA, Fang M, Bradley RK, Guo-Liang C, Lanier R, Tasian SK: Glucocorticoids Regulate the Splicing Factor MBNL1, a Potential Control Point for B-Cell Specification Blood 132(S1): abstract #2478, December 2019 Notes: Poster presentation by a collaborator at ASH annual meeting; Orlando, Florida.
Hurtz C, Wertheim G, Bhansali RDS, Lehman A, Jeschke G, Crispino JD, Besson T, Tasian SK*, Carroll M* (*co-senior authors): DYRK1A is Regulated by Oncogenic KMT2A and Required for Survival of KMT2A-Rearranged Acute Lymphoblastic Leukemia. Blood 132(S1): abstract #2742, December 2019 Notes: Poster presentation by collaborator at ASH annual meeting; Orlando, Florida.
Liou Am Van Arnam J, Pillai V, Seif AE, Tasian SK, Phillips CA: Transient atypical monocytosis aftere a/b Tt-cell-depleted haploidentical hematopoietic stem cell transplantation. Pediatr Blood Cancer December 2019.
Liou Angela, Van Arnam John, Pillai Vinodh, Seif Alix E, Tasian Sarah K, Phillips Charles A: Transient atypical monocytosis after α/β T-cell-depleted haploidentical hematopoietic stem cell transplantation. Pediatric blood & cancer Page: e28139, Dec 2019.
Lamble Adam J, Tasian Sarah K: Opportunities for immunotherapy in childhood acute myeloid leukemia. Hematology. American Society of Hematology. Education Program 2019(1): 218-225, Dec 2019.
Zimmerman JAO, Fang M, Modi A, Dupuy A, Tasian SK, Pufall MA: PI3Kd Inhibition Enhances Sensitivity of Primary High-Risk Childhood B-Cell Acute Lymphoblastic Leukemia Cells to Glucocorticoid Chemotherapy. Blood 132(S1): abstract #2572, December 2019 Notes: Poster presentation by a collaborator at ASH annual meeting; Orlando, Florida.
Lamble AJ and Tasian SK: Opportunities for immunotherapy in childhood acute myeloid leukemia. Blood Advances 3(22): 3750-3758, November 2019.